Keywords: Daiichi Sankyo, Edoxaban, Venous thromboembolism, Phase III trial

Daiichi Sankyo initiates major Phase III trial for edoxaban in venous thromboembolism

Article | 04 February 2010

Print This

Japanese drug major Daiichi Sankyo has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in